Tuesday, March 25, 2014

Cyclacel reported earnings after the market closed with an update on phase 3 enrollment in AML

Cyclacel (CYCC) reported earnings after the market closed today and provided an updated on enrollment for it's phase 3 trial of it's lead compound to treat AML in elderly patients.  They have expanded into approximately 80 sites which brings total enrolling sites to approximately 120 after you included the 40 sites in the United States.  They have now enrolled 60% of patients in the trial and expect to complete enrollment by the end of the year with top line results in 2015.  They have an agreed upon Special Protocol Assessment with the FDA for this trial.  They are also evaluating the opportunity to begin a second phase 3 trial for the same compound to treat MDS and expect to provide an update on this opportunity later this year. 

I own a small position of 2,000 shares in Cyclacel.  The company has a small market cap of $68 million with a phase 3 trial expecting results in 2015 in an indication (AML) which needs improved treatment options so I believe the stock is a good value. 

No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com